A detailed history of Personal Capital Advisors Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Personal Capital Advisors Corp holds 8,404 shares of HALO stock, worth $411,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,404
Previous 8,404 -0.0%
Holding current value
$411,796
Previous $332,000 43.98%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$31.97 - $41.06 $48,050 - $61,713
-1,503 Reduced 15.17%
8,404 $335,000
Q1 2021

May 14, 2021

SELL
$39.51 - $51.45 $33,464 - $43,578
-847 Reduced 7.88%
9,907 $413,000
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $51 - $87
2 Added 0.02%
10,754 $459,000
Q2 2020

Aug 12, 2020

BUY
$16.25 - $26.81 $174,720 - $288,261
10,752 New
10,752 $288,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.83B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Personal Capital Advisors Corp Portfolio

Follow Personal Capital Advisors Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Personal Capital Advisors Corp, based on Form 13F filings with the SEC.

News

Stay updated on Personal Capital Advisors Corp with notifications on news.